Combination therapy with interferon alpha and beta to chronic hepatitis C.
Combination therapy with interferon alpha and beta to chronic hepatitis C.
复制标题
干扰素α和β联合治疗慢性丙型肝炎。
作者：
N. Horiike;H. Hino;Yoshikazu Tanaka;H. Miyaoka;S. Miki;S. Yamashita;B. Matsuura;Y. Kubo;Y. Ikeda;S. F. Akbar;T. Masumoto;K. Michitaka;M. Onji
为了提高慢性丙型肝炎（CHC）的持续应答（SR）率，我们尝试了干扰素（IFN）α和β的联合治疗。将50例患者分为4组：1H组（n=9），HCV血清1型和高HCV-RNA滴度（> 6 log copies/ml）; 1 L组（n=11），HCV血清1型和低HCV-RNA滴度（<6 log copies/ml）; 2 H组（n=23），HCV血清2型和高HCV-RNA滴度; 2L组（n=7），HCV血清2型和低HCV-RNA滴度。他们被给予768 MIU的总剂量，其中包括天然IFN β（6 MIU），每天一次，连续28天，然后天然IFN α（10 MIU），每周三次，持续20周。49例CHC患者接受总剂量为480 MIU的IFN α作为单一治疗组。联合组SR率分别为62%、44%、45%、70%、86%。在单组中，SR率分别为45%、14%、58%、60%和82%。联合组与单用组SR发生率无显著性差异。但在HCV-RNA滴度为67 log copies/ml的1H组患者中，联合组SR发生率（67%，4/6）显著高于单用组（18%，3/17）（p<0.05）。这些数据表明IFN α和IFN β联合治疗具有中等高HCV-RNA滴度的血清1型CHC是有用的。
To increase the sustained response (SR) rate in chronic hepatitis C (CHC), we tried a combination therapy with interferon (IFN) alpha and beta. Fifty patients were grouped into 4 groups: group 1H (n=9), HCV serotype 1 and high HCV-RNA titer (over 6 log copies/ml); group 1L (n=11), HCV serotype 1 and low HCV-RNA titer (less than 6 log copies/ml); group 2H (n=23), HCV serotype 2 and high HCV-RNA titer; group 2L (n=7), HCV serotype 2 and low HCV-RNA titer. They were given a total dose of 768 MIU which included natural IFN beta (6 MIU) once daily for 28 consecutive days and then natural IFNalpha (10 MIU) three times a week for 20 weeks. Forty-nine patients with CHC receiving IFN alpha at total dose of 480 MIU served as single therapy group. In combination group, SR rate was achieved in 62%, 44% in 1H, 45% in 1L, 70% in 2H, and 86% in 2L, respectively. In single group, SR rate was achieved in 45, 14, 58, 60, and 82%, respectively. There was no significant difference for SR rate between combination group and single group. However, in patients with HCV-RNA titer between 6-7 log copies/ml of 1H group, SR rate in combination group (67%, 4/6) was significantly higher than that of single group (18%, 3/17) (p<0.05). These data suggest the usefulness of combination therapy with IFN alpha and beta in CHC with serotype 1 having moderately high HCV-RNA titer.